These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1056 related articles for article (PubMed ID: 1909705)

  • 1. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization.
    Waldstreicher J; Santoro NF; Hall JE; Filicori M; Crowley WF
    J Clin Endocrinol Metab; 1988 Jan; 66(1):165-72. PubMed ID: 2961784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of a single serum LH measurement in women with cycle disturbances: discrepancies between immunoreactive and bioactive hormone estimates.
    Fauser BC; Pache TD; Hop WC; de Jong FH; Dahl KD
    Clin Endocrinol (Oxf); 1992 Nov; 37(5):445-52. PubMed ID: 1486695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea.
    Burger CW; Korsen T; van Kessel H; van Dop PA; Caron FJ; Schoemaker J
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1126-32. PubMed ID: 3932449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
    Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO.
    Lobo RA; Granger L; Goebelsmann U; Mishell DR
    J Clin Endocrinol Metab; 1981 Jan; 52(1):156-8. PubMed ID: 6778890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome.
    van der Westhuizen S; van der Spuy ZM
    Ultrasound Obstet Gynecol; 1996 May; 7(5):335-41. PubMed ID: 8774098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which hormone tests for the diagnosis of polycystic ovary syndrome?
    Robinson S; Rodin DA; Deacon A; Wheeler MJ; Clayton RN
    Br J Obstet Gynaecol; 1992 Mar; 99(3):232-8. PubMed ID: 1296589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels.
    Lado-Abeal J; Rodriguez-Arnao J; Newell-Price JD; Perry LA; Grossman AB; Besser GM; Trainer PJ
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3083-8. PubMed ID: 9745407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects.
    Spinder T; Spijkstra JJ; van den Tweel JG; Burger CW; van Kessel H; Hompes PG; Gooren LJ
    J Clin Endocrinol Metab; 1989 Jul; 69(1):151-7. PubMed ID: 2471710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries.
    Anttila L; Koskinen P; Kaihola HL; Erkkola R; Irjala K; Ruutiainen K
    Fertil Steril; 1992 Oct; 58(4):697-702. PubMed ID: 1426312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of androgen blockade on granulosa cell estradiol production after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome.
    Mehta RV; Malcom PJ; Chang RJ
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3503-6. PubMed ID: 16804036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease.
    Anttila L; Ding YQ; Ruutiainen K; Erkkola R; Irjala K; Huhtaniemi I
    Fertil Steril; 1991 Jun; 55(6):1057-61. PubMed ID: 1903726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function.
    Okon MA; Laird SM; Tuckerman EM; Li TC
    Fertil Steril; 1998 Apr; 69(4):682-90. PubMed ID: 9548158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hormonal response of patients with polycystic ovarian disease to subcutaneous low frequency pulsatile administration of luteinizing hormone-releasing hormone.
    Hurwitz A; Rosenn B; Palti Z; Ebstein B; Har-Nir R; Ron M
    Fertil Steril; 1986 Sep; 46(3):378-84. PubMed ID: 2943606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian 17-ketosteroid reductase deficiency as a possible cause of polycystic ovarian disease.
    Toscano V; Balducci R; Bianchi P; Mangiantini A; Sciarra F
    J Clin Endocrinol Metab; 1990 Aug; 71(2):288-92. PubMed ID: 2166066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
    Holte J; Bergh T; Gennarelli G; Wide L
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.